The full content of Annals is available to subscribers

Subscribe/Learn More  >
Reviews |

Angiotensin Converting Enzyme Inhibitors and Progressive Renal Insufficiency: Current Experience and Future Directions

William F. Keane, MD; Sharon Anderson, MD; Mattias Aurell, MD; Dick de Zeeuw, MD; Robert G. Narins, MD; and Gail Povar, MD
[+] Article, Author, and Disclosure Information

Requests for Reprints: William F. Keane, MD, Division of Nephrology, Department of Medicine, Hennepin County Medical Center, 701 Park Avenue, Minneapolis, MN 55415.

Current Author Addresses: Dr. Keane: Division of Nephrology, Department of Medicine, Hennepin County Medical Center, 701 Park Avenue, Minneapolis, MN 55415.

Dr. Anderson: Renal Division, Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115.

Dr. Aurell: Department of Nephrology, Sahlgrenska sjukhuset, S-413 45 Göteborg, Sweden.

Dr. de Zeeuw: Department of Internal Medicine, Room E403, Oostersingel 59, 9713 EZ Groningen, The Netherlands.

Dr. Narins: Temple University Health Sciences Center, 3401 North Broad Street, 580 PP, Philadelphia, PA 19140.

Dr. Povar: Room 2B-419, Department of Health Care Sciences, George Washington University School of Medicine, 2150 Pennsylvania Avenue NW, Washington, D.C. 20007.

© 1989 American College of PhysiciansAmerican College of Physicians

Ann Intern Med. 1989;111(6):503-516. doi:10.7326/0003-4819-111-6-503
Text Size: A A A

Study Objective: To review the rationale for using angiotensin converting enzyme (ACE) inhibitors in progressive renal disease, and to evaluate the experience with these agents in patients with hypertension and renal insufficiency.

Data Identification: Experimental and clinical studies published from January 1977 to November 1988 were identified by searching the literature and by extensive hand searching of bibliographies of identified articles.

Study Selection: Experimental studies of glomerular function during therapy with ACE inhibitors or other antihypertensive regimens were reviewed. Series using ACE inhibitors for treating hypertensive patients with renal disease were evaluated and reports of adverse events were studied.

Results of Data Synthesis: Experimentally, ACE inhibitors seem to decrease glomerular injury by reducing both systemic and glomerular hypertension. Clinically, ACE inhibitors reduce systemic blood pressure in hypertensive patients with diabetic and nondiabetic renal disease without causing dramatic changes in glomerular filtration rate or renal blood flow. Most studies of nondiabetic renal insufficiency suggest that proteinuria is reduced in most patients. However, no long-term controlled study on the effect of ACE inhibitors on the progression rate of nondiabetic renal disease has been completed. ACE inhibitors have not yet been approved by the Food and Drug Administration (FDA) for treating or preventing progressive renal disease. Such use would therefore be considered "innovative" therapy.

Conclusions: ACE inhibitors are tolerated by azotemic patients, although transient reductions in renal function can occur. Patients with bilateral renal insufficiency or low cardiac output are at increased risk for developing reversible acute renal insufficiency. Hyperkalemia may occur, particularly in patients with diabetes or severe renal insufficiency. In many patients with renal disease, ACE inhibitors dramatically reduce proteinuria, but whether they also reduce the rate of progression of renal disease remains unproved.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.